Plain-English translation of NCT05482516 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether two medications— and —can help prevent cancer from returning in people with colon, stomach, pancreatic, liver, or bile duct cancer who have completed surgery and standard treatment. You would be eligible if blood tests show cancer DNA is still present even though scans show no visible disease. The study will give you these medications as an IV infusion every three weeks for up to one year.
After surgery and treatment, some patients have cancer DNA circulating in their blood even though scans look normal—a sign that microscopic disease may still be present. This trial is testing whether starting this medication early in these patients can prevent the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
You would visit the study site once every three weeks to receive two medications as IV infusions on the same day. Each cycle lasts 21 days, and you would continue for up to 12 months unless your cancer returns, your blood tests become negative, you experience severe side effects, or you choose to stop. The study team will monitor you closely with blood tests and imaging to see how you respond to the treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States